Sahebnasagh, Adeleh and Rezai Ghaleno, Hassan and Najmeddin, Farhad and Najafi, Atabak and Safdari, Mohammadreza and Habtemariam, Solomon (2020) A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19. Arch Med Res.
|
Text
A Perspective on Erythropoietin as a Potential.pdf Download (257kB) | Preview |
Abstract
The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in December 2019 has rapidly spread to become a global pandemic. This article summarizes the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis which is now called COVID-19. As with other coronavirus infection, the lethality of COVID-19 is associated with respiratory dysfunction due to overexpression of proinflammatory cytokines induced by the host immune responses. The resulting cytokine storm leads to the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Erythropoietin, well known for its role in the regulation of erythropoiesis, may have protective effects against ALI/ARDS induced by viral and other pathogens. EPO exerts antiapoptotic and cytoprotective properties under various pathological conditions. With a high safety profile, EPO promotes the production of endothelial progenitor cells and reduce inflammatory processes through inhibition of the nuclear factor-κB (NF-κB) and JAK-STAT3 signaling pathways. Thus, it may be considered as a safe drug candidate for COVID-19 patients if given at the early stage of the disease. The potential effects of erythropoietin on different aspects of ALI/ARDS associated with SARS-CoV-2 infection are reviewed.
Item Type: | Article |
---|---|
Subjects: | R Medicine > R Medicine (General) |
Divisions: | Faculty of Medicine, Health and Life Sciences > School of Medicine |
Depositing User: | lorestan university |
Date Deposited: | 19 Dec 2020 09:50 |
Last Modified: | 19 Dec 2020 09:50 |
URI: | http://eprints.lums.ac.ir/id/eprint/2520 |
Actions (login required)
View Item |